key: cord-1054807-aqg1aaes authors: Perez-Garcia, F.; Perez-Tanoira, R.; Iglesias, M. E.; Romanyk, J.; Arroyo, T.; Gomez-Herruz, P.; Gonzalez, R.; Cuadros-Gonzalez, J. title: Comparative evaluation of six immunoassays for the detection of antibodies against SARS-CoV-2 date: 2020-09-09 journal: nan DOI: 10.1101/2020.09.08.20190488 sha: 5555efc4f5ff5f75b4492c890acff66dc30b2544 doc_id: 1054807 cord_uid: aqg1aaes Objectives: Serologic techniques can serve as a complement to diagnose SARS-CoV-2 infection. The objective of our study was to compare the diagnostic performance of six immunoassays to detect antibodies against SARS-CoV-2: three lateral flow immunoassays (LFAs), one ELISA and two chemiluminescence assays (CLIAs). Methods: We evaluated three LFAs (Alltest, One Step and SeroFlash), one ELISA (Dia.Pro) and two CLIAs (Elecsys and COV2T). To assess the specificity, 60 pre-pandemic sera were used. To evaluate the sensitivity, we used 80 serum samples from patients with positive PCR for SARS-CoV-2. Agreement between techniques was evaluated using the kappa score (k). Results: All immunoassays showed a specificity of 100% except for SeroFlash (96.7%). Overall sensitivity was 61.3%, 73.8%, 67.5%, 85.9%, 88.0% and 92.0% for Alltest, One Step, SeroFlash, Dia.Pro, Elecsys and COV2T, respectively. Sensitivity increased throughout the first two weeks from the onset of symptoms, reaching sensitivities over 85% from 14 days for all LFAs, being One Step the most sensitive (97.6%), followed by SeroFlash (95.1%). Dia.Pro, Elecsys and COV2T showed sensitivities over 97% from 14 days, being 100% for COV2T. One Step showed the best agreement results among LFAs, showing excellent agreement with Dia.Pro (agreement=94.2%, k=0.884), COV2T (99.1%, k=0.981) and Elecsys (97.3%, k=0.943). Dia.Pro, COV2T and Elecsys also showed excellent agreement between them. Conclusions: One Step, Dia.Pro, Elecsys and COV2T obtained the best diagnostic performance results. All these techniques showed a specificity of 100% and sensitivities over 97% from 14 days after the onset of symptoms, as well as excellent levels of agreement. Since the beginning of the pandemic due to SARS-CoV-2 in Wuhan in December 57 2019, the virus has caused as of August 19, 2020, more than 21 million cases and 58 775,000 deaths worldwide [1] . An early and accurate diagnosis of SARS-CoV-2 59 infection is essential for the adequate management of COVID-19 patients and the 60 establishment of infection control measures in order to contain this pandemic. 101 We considered a positive result for samples in which IgG, IgM or both of them were 102 detected. Specificity and sensitivity with 95% confidence intervals (95%CI) were 103 calculated using the results from negative controls and positive PCR patients, 104 respectively. Sensitivity was evaluated globally and also according to the time from 105 the onset of symptoms. Agreement between different techniques was evaluated 106 using the Cohen's kappa score [9] . Statistical analysis was performed using Stata/IC 107 13.1 (StataCorp, Texas, USA). . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20190488 doi: medRxiv preprint Overall serologic results from the different techniques are summarized in Table 1 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20190488 doi: medRxiv preprint Our study shows that One Step, Dia.Pro, Elecsys and COV2T achieved the best 129 diagnostic performance results. All these techniques showed a specificity of 100% 130 and sensitivities over 97% from 14 days after the onset of symptoms, as well as 131 excellent levels of agreement between them. in the two studies that evaluated the diagnostic performance of Elecsys, the reported 145 sensitivities and specificities were lower than those obtained in our study [13, 16] . In our experience, Dia.Pro, Elecsys and COV2T obtained excellent levels of sensitivity, 147 specificity and agreement. We also showed that those LFAs that use recombinant 148 nucleocapsid and spike antigens (One Step and SeroFlash) could achieve practically 149 the same diagnostic performance results than ELISA and CLIAs. At the beginning of 150 its development, the usefulness of LFAs was questioned due to a lack of official 151 performance validations [5, 17] . Nowadays these tests have demonstrated their 152 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20190488 doi: medRxiv preprint usefulness and reliability in epidemiological studies [7] , and also in the diagnosis of 153 pneumonia of unknown etiology with negative PCR for SARS-CoV-2 [18]. Our study presents some limitations. First, it is a retrospective study that has been 155 conducted in a single institution. Further prospective multicenter studies are 156 necessary to reinforce our findings. Second, sensitivity evaluation of CLIAs was 157 performed only over 50 sera, due to insufficient simple volume. However, the 158 samples that could not be analyzed belonged to the first two weeks after the onset is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 9, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 9, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 9, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 9, 2020. . https: //doi.org/10.1101 //doi.org/10. /2020 [18] F. Pérez-García, R. Pérez-Tanoira, J. Romanyk, T. Arroyo, P. Gómez-Herruz, J. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20190488 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20190488 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 9, 2020 . . https://doi.org/10.1101 /2020 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20190488 doi: medRxiv preprint Abbreviations: -: not reported data; sensitivity 14 days: sensitivity from 14 days after the onset of symptoms; N: 351 Nucleocapsid; S: Spike; Ab: antibodies; EBV: Epstein-Barr Virus; CMV: Cytomegalovirus; ELISA: enzyme-linked immunoassay